ELI LILLY AND COMPANY (LLY) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Available-for-sale Securities, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 47.74B USD | Liabilities, Current |
| Cash and equivalents | 8.95B USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | Available-for-sale Securities, Current |
| Customer receivables | 20.08B USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 16.79B USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $47.74B | $8.95B | (m) | $20.08B | $16.79B | (m) |
| 2026-03-31 | (m) | $36.63B | $5.28B | (m) | $18.43B | $14.53B | (m) |
| 2025-12-31 | (m) | $35.23B | $7.27B | (m) | $17.76B | $13.74B | (m) |
| 2025-09-30 | (m) | $40.14B | $9.79B | (m) | $16.11B | $12.18B | (m) |
| 2025-06-30 | (m) | $39.02B | $3.38B | (m) | $14.17B | $11.01B | (m) |
| 2025-03-31 | (m) | $30.07B | $3.09B | (m) | $12.04B | $9.31B | (m) |
| 2024-12-31 | (m) | $28.38B | $3.27B | (m) | $11.01B | $7.59B | (m) |
| 2024-09-30 | (m) | $24.67B | $3.37B | (m) | $10.29B | $7.46B | (m) |
| 2024-06-30 | (m) | $27.12B | $3.22B | (m) | $11.03B | $6.48B | (m) |
| 2024-03-31 | (m) | $18.60B | $2.46B | (m) | $7.89B | $6.10B | (m) |
| 2023-12-31 | (m) | $27.29B | $2.82B | (m) | $9.09B | $5.77B | (m) |
| 2023-09-30 | (m) | $22.00B | $2.38B | (m) | $8.17B | $4.90B | (m) |
| 2023-06-30 | (m) | $18.91B | $2.69B | (m) | $7.52B | $4.80B | (m) |
| 2023-03-31 | (m) | $16.01B | $3.55B | (m) | $7.53B | $4.54B | (m) |
| 2022-12-31 | (m) | $17.14B | $2.07B | (m) | $6.90B | $4.31B | (m) |
| 2022-09-30 | (m) | $15.65B | $2.62B | (m) | $6.72B | $3.83B | (m) |
| 2022-06-30 | (m) | $15.62B | $2.62B | (m) | $6.36B | $3.90B | (m) |
| 2022-03-31 | (m) | $13.39B | $2.46B | (m) | $6.32B | $3.89B | (m) |
| 2021-12-31 | (m) | $15.05B | $3.82B | (m) | $6.67B | $3.89B | (m) |
| 2021-09-30 | (m) | $13.68B | $3.79B | (m) | $5.91B | $3.91B | (m) |
| 2021-06-30 | (m) | $15.09B | $3.22B | (m) | $5.83B | $3.82B | (m) |
| 2021-03-31 | (m) | $11.71B | $3.00B | (m) | $5.59B | $3.66B | (m) |
| 2020-12-31 | (m) | $12.48B | $3.66B | (m) | $5.88B | $3.98B | (m) |
| 2020-09-30 | (m) | $11.98B | $3.60B | (m) | $4.89B | $3.56B | (m) |
| 2020-06-30 | (m) | $11.99B | $2.37B | (m) | $4.83B | $3.31B | (m) |
| 2020-03-31 | (m) | $12.61B | $1.70B | (m) | $5.11B | $3.10B | (m) |
| 2019-12-31 | (m) | $11.78B | $2.34B | (m) | $4.55B | $3.19B | (m) |
| 2019-09-30 | (m) | $10.83B | (m) | (m) | $4.44B | $3.10B | (m) |
| 2019-06-30 | (m) | $11.86B | $2.29B | (m) | $4.61B | $3.18B | (m) |
| 2019-03-31 | (m) | $11.24B | $2.04B | (m) | $4.20B | $3.06B | (m) |
| 2018-12-31 | (m) | $11.89B | $8.00B | (m) | $5.25B | $4.11B | (m) |
| 2018-09-30 | (m) | $10.83B | $8.96B | (m) | $4.86B | $4.12B | (m) |
| 2018-06-30 | (m) | $13.06B | $6.82B | (m) | $4.82B | $4.16B | (m) |
| 2018-03-31 | (m) | $11.55B | $3.08B | (m) | $4.50B | $4.63B | (m) |
| 2017-12-31 | (m) | $14.54B | $6.54B | (m) | $4.55B | $4.46B | (m) |
| 2017-09-30 | (m) | $12.67B | $3.72B | (m) | $4.40B | $4.41B | (m) |
| 2017-06-30 | (m) | $11.29B | $3.07B | (m) | $4.35B | $4.35B | (m) |
| 2017-03-31 | (m) | $10.45B | $2.62B | (m) | $4.02B | $4.04B | (m) |
| 2016-12-31 | (m) | $10.99B | $4.58B | (m) | $4.03B | $3.56B | (m) |
| 2016-09-30 | (m) | $8.27B | $3.49B | (m) | $3.85B | $3.88B | (m) |
| 2016-06-30 | (m) | $8.40B | $3.24B | (m) | $3.95B | $3.76B | (m) |
| 2016-03-31 | (m) | $7.34B | $2.31B | (m) | $3.62B | $3.74B | (m) |
| 2015-12-31 | $7.96B | $8.23B | $3.67B | $785.40M | $3.51B | $3.45B | 0.97× |
| 2015-09-30 | (m) | $8.30B | $3.24B | (m) | $3.40B | $3.42B | (m) |
| 2015-06-30 | (m) | $8.23B | $3.32B | (m) | $3.35B | $3.29B | (m) |
| 2015-03-31 | (m) | $8.34B | $3.06B | (m) | $3.14B | $2.98B | (m) |
| 2014-12-31 | (m) | $11.21B | $3.87B | (m) | $3.23B | $2.74B | (m) |
| 2014-09-30 | (m) | $7.57B | $3.17B | (m) | $3.05B | $2.84B | (m) |
| 2014-06-30 | (m) | $7.42B | $3.77B | (m) | $3.19B | $3.19B | (m) |
| 2014-03-31 | (m) | $6.63B | $3.89B | (m) | $3.00B | $2.97B | (m) |
| 2013-12-31 | (m) | $8.92B | $3.83B | (m) | $3.43B | $2.93B | (m) |
| 2013-09-30 | (m) | $8.08B | $4.37B | (m) | $3.44B | $2.97B | (m) |
| 2013-06-30 | (m) | $8.41B | $3.79B | (m) | $3.58B | $2.73B | (m) |
| 2013-03-31 | (m) | $7.59B | $3.94B | (m) | $3.44B | $2.58B | (m) |
| 2012-12-31 | (m) | $8.39B | $4.02B | (m) | $3.34B | $2.64B | (m) |
| 2012-09-30 | (m) | $6.96B | $5.32B | (m) | $3.27B | $2.55B | (m) |
| 2012-06-30 | (m) | $6.61B | $4.35B | (m) | $3.18B | $2.32B | (m) |
| 2012-03-31 | (m) | $6.55B | $4.12B | (m) | $3.40B | $2.42B | (m) |
| 2011-12-31 | (m) | $8.93B | $5.92B | (m) | $3.60B | $2.30B | (m) |
| 2011-09-30 | (m) | $8.22B | $6.60B | (m) | $3.53B | $2.51B | (m) |
| 2011-06-30 | (m) | $8.62B | $6.11B | (m) | $3.83B | $2.87B | (m) |
| 2011-03-31 | (m) | $7.65B | $6.51B | (m) | $3.69B | $2.77B | (m) |
| 2010-12-31 | (m) | $7.10B | $5.99B | (m) | $3.49B | $2.52B | (m) |
| 2010-09-30 | (m) | $6.10B | $5.91B | (m) | $3.34B | $2.68B | (m) |
| 2010-06-30 | (m) | $6.32B | $5.16B | (m) | $3.07B | $2.17B | (m) |
| 2010-03-31 | (m) | $5.66B | $4.73B | (m) | $3.19B | $2.47B | (m) |
| 2009-12-31 | (m) | $6.57B | $4.46B | (m) | $3.34B | $2.85B | (m) |
| 2009-09-30 | (m) | $6.07B | $3.85B | (m) | $3.02B | $3.13B | (m) |
| 2009-06-30 | (m) | $6.99B | $3.32B | (m) | $2.84B | $3.00B | (m) |
| 2009-03-31 | (m) | (m) | $3.31B | (m) | (m) | (m) | (m) |
| 2008-12-31 | (m) | $13.11B | $5.50B | (m) | $2.78B | $2.49B | (m) |
| 2008-09-30 | (m) | (m) | $4.35B | (m) | (m) | (m) | (m) |
| 2008-06-30 | (m) | (m) | $2.87B | (m) | (m) | (m) | (m) |
| 2007-12-31 | (m) | (m) | $3.22B | (m) | (m) | (m) | (m) |
| 2006-12-31 | (m) | (m) | $3.11B | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |